Starpharma completes chairman succession
Starpharma’s (ASX:SPL) long-serving chairman Peter Bartels has retired from his role and been replaced with chair-elect Rob Thomas.
Bartels has been non-executive chairman of Starpharma since 2003. He announced his decision to retire in November last year as part of a board succession plan.
Thomas joined the company the following month as non-executive director and chair-elect. He has had more than 35 years of experience in the financial services sector at Potter Partners (now UBS), County Natwest and Citigroup.
Thomas is currently a non-executive director in healthcare companies including Heartware International, Biotron (ASX:BIT) and REVA Medical (ASX:RVA). He was the former non-executive chairman of Heartware International.
In a statement announcing the change of guard, the Starpharma board said Bartels had played a major role in transforming the company into a business with multiple products near commercial launch.
“I have had the pleasure of working beside Peter over the last six months and I take over as chairman at a time when the fundamentals of the Starpharma business are strong,” Thomas commented.
Starpharma (ASX:SPL) shares were trading 1.67% higher at $0.61 as of around 1 pm on Monday.
Prenatal stress leaves a molecular mark on newborns
An international study has uncovered how stress experienced during pregnancy can affect newborns...
More effective antibiotic found for Lyme disease
Researchers have found that piperacillin, an antibiotic in the same class as penicillin,...
Why do our waistlines expand in middle age?
A new preclinical study highlights the importance of controlling new fat-cell formation to...
